NCT01485406已完成1 期
Safety and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine 2830930A When Administered as a Single Dose in Healthy Toddlers Aged 12-23 Months
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 5
- 主要终点
- Occurrence of grade 3 unsolicited adverse events with relationship to vaccination
研究概览
简要总结
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the GSK Biologicals' pneumococcal vaccine 2830930A in toddlers aged 12 to 23 months at study entry.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Months 至 23 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LARs) can and will comply with the requirements of the protocol.
- •A male or female between, and including 12 to 23 months of age at the time of vaccination.
- •Written informed consent obtained from the parents/LAR(s) of the subject.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Born after a gestation period of at least 36 weeks.
- •Previously completed three-dose vaccination course with Synflorix.
排除标准
- •Child in care.
- •Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs since birth.
- •Planned administration/administration of a vaccine containing diphtheria- or tetanus- toxoid or CRM197 and not foreseen by the study protocol during any time of the study period, or of any other vaccines not foreseen by the protocol in the period starting from 30 days before the vaccine dose and ending 30 days after, with the exception of licensed influenza vaccines.
- •The licensed influenza vaccines are always allowed, even if concomitantly administered with the study vaccines but should be documented in the "Concomitant vaccination" of the electronic Case Report Form.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination
- •Family history of congenital or hereditary immunodeficiency.
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).
- •Major congenital defects or serious chronic illness, including Kawasaki's syndrome.
- •History of any neurological disorders or seizures, including conditions such as hypotensive-hyporesponsive episodes, encephalopathy and any convulsions (afebrile and febrile).
- •Acute disease and/or fever at the time of enrolment.
- •Administration of immunoglobulins and/or any blood products within the 3 months preceding vaccination or planned administration during study period.
- •Any medical condition which might interfere with the assessment of the study objectives in the opinion of the investigator.
- •Previous receipt of a booster dose (fourth dose) of Synflorix.
- •Anaphylaxis following previous administration of vaccines.
结局指标
主要结局
Occurrence of grade 3 unsolicited adverse events with relationship to vaccination
时间窗: Within 31 days (Day 0-Day 30) after vaccination
Occurrence of serious adverse events with relationship to vaccination
时间窗: During the entire study (from Month 0 up to Month 1)
Occurrence of each grade 3 solicited adverse event with relationship to vaccination
时间窗: Within 7 days (Day 0-Day 6) after vaccination
次要结局
- Occurrence of each unsolicited adverse event(Within 31 days (Day 0-Day 30) after vaccination)
- Evaluation of the immune responses to the components of the 2830930A vaccine(One month post-vaccination)
- Occurrence of each solicited adverse event(Within 7 days (Day 0-Day 6) after vaccination)
- Occurrence of serious adverse event(During the entire study (from Month 0 up to Month 1))
研究者
研究点 (5)
Loading locations...
相似试验
已完成
3 期
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and OlderHerpes Zoster VaccineHerpes ZosterNCT02045836GlaxoSmithKline865
已完成
3 期
Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 YearsHerpes ZosterNCT01777321GlaxoSmithKline60
已完成
3 期
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and OlderHerpes ZosterNCT01954251GlaxoSmithKline829
已完成
3 期
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and OlderHerpes ZosterNCT02052596GlaxoSmithKline935
终止
3 期
Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in ChildrenInfluenzaNCT01014091GlaxoSmithKline60